Cd45 inhibitors

US6939896B2 · kind B2 · utility

Assignee

• ASTRAZENECA AB · SE

Inventors

• Marc Chapdelaine · Wilmington, US
• Katherine Knappenberger · Wilmington, US
• Gary Steelman · Wilmington, US
• Suzanne J. Suchard · Wilmington, US
• Linda Sygowski · Wilmington, US
• Rebecca Urbanek · Wilmington, US
• Chris Allan Veale · Newark, US

Key dates

• Filing date: Dec 18, 2000
• Grant date: Sep 6, 2005
• Expiry date: May 1, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C69/95
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Q1 at each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C1-C3) alkyl and C(O)phenyl, and Q2 is selected from hydrogen, halogen, O—(C1-C3)alkyl, O—(C1-C3)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NO2 or halogen, and indolyl may be substituted with (C1-C3)alkyl or phenyl